Many genes of moderate penetrance that are increasingly being tested in PCa multigene panels can provide information for targeted therapy eligibility and have additional associated cancer risks impacting patients and their families, such as CHEK2 (breast and colorectal cancer risk), PALB2 (breast and pancreatic cancer risk), and ATM (breast and pancreatic cancer risk) [4,6,7]. This evidence concerns the gene CHEK2 and familial pancreatic carcinoma.